Brief: Eyepoint Pharmaceuticals Announces Phase 3 Program Initiation For Duravy In Diabetic Macular Edema
14/10/2025 21:21
Oct 14 (Reuters) - EyePoint Pharmaceuticals Inc EYPT.O: EYEPOINT PHARMACEUTICALS INC - ANNOUNCES PHASE 3 PROGRAM INITIATION FOR DURAVY IN DIABETIC MACULAR EDEMA Source text: ID:nGNX1Rxf5T Further company coverage: EYPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on EyePoint
See all newsUS RESEARCH ROUNDUP-Axon Enterprise, Williams-Sonoma, Xcel Energy
US STOCKS ON THE MOVE-CoreWeave, Moderna, Datadog
U.S. STOCKS ON THE MOVE-Amazon, CoreWeave, Moderna
U.S. STOCKS ON THE MOVE-Centrus Energy, Disc Medicine, Crypto
EyePoint to halve workforce after experimental drug fails second late-stage trial (updated)